New drug cocktail aims to extend remission in relapsed myeloma
NCT ID NCT01054196
First seen Apr 18, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests whether adding lenalidomide to the standard chemotherapy (melphalan) before a stem cell transplant can improve outcomes for people with relapsed multiple myeloma. About 52 participants will receive the combination, followed by maintenance lenalidomide. The goal is to find the safest dose and see if it lengthens the time the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.